

press release

Novo Nordisk UK confident of Hormone Replacement Therapy (HRT) supply amid Coronavirus outbreak

Gatwick, March 24 2020 – Novo Nordisk is dedicated to ensuring medicine supplies are unaffected during the current Coronavirus outbreak. Our patients, the NHS and our people are at the heart of everything we do.

We are aware of the ongoing HRT shortages being experienced by some pharmaceutical companies, and how distressing this must be for those women affected.

Novo Nordisk stocks are not affected by these current supply issues and, as always, our priority is ensuring that people receive the care and treatment that they need.

As such, we are working closely with the Government to continue to ensure our HRT products are available for all of those in need, including women who were previously prescribed alternatives.

We are planning for all future contingencies to ensure a strong continuation of supply to bring our essential medicines into the UK. As it stands, Novo Nordisk is in a good position, with high stock levels in the UK, to continue to ensure patients get access to the medicines and treatments they need. We encourage healthcare professionals to prescribe at a normal rate to allow us to plan our stock levels and to distribute our medicines and treatments in our normal way.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, "During this unprecedented time, Novo Nordisk is doing all we can to respond to the Coronavirus outbreak. Our first commitment is to ensure that our patients continue to get access to the medicine that they need. We believe our preparations are robust and we have taken all necessary steps to ensure continuity of supply to the UK patients we serve."

If women have any concerns regarding HRT, please <https://www.womens-health-concern.org/>.

-END-

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people with obesity,

Novo Nordisk Ltd
Corporate Communications

3 City Place Beehive Ring Road
Gatwick West Sussex RH6 0PA

Telephone:
+44 1293 613555

Internet:
www.novonordisk.co.uk

haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.co.uk

*Juliet Scott
Abby Purdy*

*+44 (0)7557490116
+44 (0)787 2506 607*

*zjls@novonordisk.com
Abby.Purdy@Syneoshealth.com*

Novo Nordisk Ltd
Corporate Communications

3 City Place Beehive Ring Road
Gatwick West Sussex RH6 0PA

Telephone:
+44 1293 613555

Internet:
www.novonordisk.co.uk

Job ID: UK20NNG00017
Date of Prep – March 2020